tbuckley/cabot-search huggingface dataset:
AB1388 Lifestyle in patients with systemic lupus erythematosus and metabolic syndrome. intervention to explore self-knowledge, perception and improvement
Authors: I. Etchegaray Morales, M. Garcia Carrasco, A. García-Villaseñor, S. Méndez-Martínez, Á. Montiel. Jarquín, N.E. Alonso García, E. Jiménez Herrera, P. Soto Santillan, J.L. Gandara Ramirez, C. Mendoza Pinto
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Lifestyle in patients with systemic lupus erythematosus and metabolic syndrome. Intervention to explore self-knowledge, perception and improvement. Ivet Etchegaray-Morales<sup>1</sup>, Mario García-Carrasco<sup>1,2</sup>, Arturo García-Villaseñor<sup>1,3,4</sup>, Socorro Méndez-Martínez<sup>2</sup>, Álvaro Montiel Jarquín<sup>1,2</sup>. Norma Edith Alonso García<sup>5</sup>, Erick Jiménez Herrera, Pamela Soto Santillán <sup>1,2</sup>, José Luis Gándara Ramírez<sup>1</sup>, Claudia Mendoza Pinto <sup>1,2</sup> <sup>1</sup> Medicine School Benemérita Universidad Autónoma de Puebla, Puebla, México. <sup>2</sup> Systemic Autoimmune Diseases Research Unit, Instituto Mexicano del Seguro Social, Puebla, Mexico <sup>3</sup> ARTHIL Institute <sup>4</sup> Universidad de las Américas Puebla, Puebla, Mexico. <sup>5</sup> Department of Psychology, Medicine School Benemérita Universidad Autónoma de Puebla, Puebla, México. <h3>Summary</h3> Systemic lupus erythematosus (SLE) has been associated with cardiovascular disease and metabolic syndrome (MS). A supportive educational intervention to modify lifestyle could improve morbidity and mortality in SLE patients with MS. <h3>Objectives</h3> To measure the impact of an educational intervention that improves the knowledge about disease and lifestyle in SLE patients with MS. <h3>Methods</h3> A quasi-experimental study was conducted among SLE patients with SM according to the ATP III criteria at Systemic Autoimmune Diseases Research Unit of the Regional General Hospital No. 36 of the Mexican Institute of Social Security, Puebla. Clinical educational intervention in emotional and cognitive domains in the experimental group included classroom activities and outpatient consultation, evaluating healthy lifestyle knowledge that included physical activity, feeding habits and stress management with FANTASTIC instrument. Basal and final measurements were analysed with the Wilcoxon test with SPSS v21. <h3>Results</h3> Eighty nine patients were included. Age 46.1±12.6 years,<sup>17–70</sup> weight 64.2±14.5 kg,<sup>42–137</sup> 20.2% overweight and 38% obesity, 50% education over 12 years, 49.4% housewife, 39% employed, 67% lived with a partner, SLE disease evolution 12.1±6.9 years and prednisone dose 10.2±10.8 mg/day (0–50). In the retest, disease and comorbidities knowledge was modified. The domains of lifestyle such as physical activity, family-friends and nutrition showed statistical significant changes after the intervention p&lt;0.05. <h3>Conclusions</h3> The educational intervention modified the conceptual perception of SLE and MS as well as some domains of lifestyle. <h3>Disclosure of Interest</h3> None declared
Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): 8 Year Follow up of CALGB 50403 (Alliance)
Authors: Lawrence D Kaplan, Matthew J. Maurer, Wendy Stock, Nancy L. Bartlett, Noreen Fulton, Adam Pettinger, John C. Byrd, Kristie A. Blum, Ann S. LaCasce, David Duane Hurd, Amy S. Ruppert, Francisco J. Hernandez-Ilizaliturri, John P. Leonard, Bruce Cheson
Journal: Blood (2018)
Multidisciplinary approaches for targeting the secretase protein family as a therapeutic route for Alzheimer's disease
Authors: Nalini Schaduangrat, Veda Prachayasittikul, Saowapak Choomwattana, Prapimpun Wongchitrat, Kamonrat Phopin, Wilasinee Suwanjang, Aijaz Ahmad Malik, Bruno Vincent, Chanin Nantasenamat
Journal: Medicinal Research Reviews (2019)

Abstract The continual increase of the aging population worldwide renders Alzheimer's disease (AD) a global prime concern. Several attempts have been focused on understanding the intricate complexity of the disease's development along with the on‐ andgoing search for novel therapeutic strategies. Incapability of existing AD drugs to effectively modulate the pathogenesis or to delay the progression of the disease leads to a shift in the paradigm of AD drug discovery. Efforts aimed at identifying AD drugs have mostly focused on the development of disease‐modifying agents in which effects are believed to be long lasting. Of particular note, the secretase enzymes, a group of proteases responsible for the metabolism of the β‐amyloid precursor protein (βAPP) and β‐amyloid (Aβ) peptides production, have been underlined for their promising therapeutic potential. This review article attempts to comprehensively cover aspects related to the identification and use of drugs targeting the secretase enzymes. Particularly, the roles of secretases in the pathogenesis of AD and their therapeutic modulation are provided herein. Moreover, an overview of the drug development process and the contribution of computational (in silico) approaches for facilitating successful drug discovery are also highlighted along with examples of relevant computational works. Promising chemical scaffolds, inhibitors, and modulators against each class of secretases are also summarized herein. Additionally, multitarget secretase modulators are also taken into consideration in light of the current growing interest in the polypharmacology of complex diseases. Finally, challenging issues and future outlook relevant to the discovery of drugs targeting secretases are also discussed.
Multibeat Right Ventricular–Arterial Coupling during a Positive Acute Vasoreactivity Test
Authors: Khodr Tello, Antonia Dalmer, Faeq Husain-Syed, Werner Seeger, Robert Naeije, Hossein A. Ghofrani, Henning Gall, Manuel J. Richter
Journal: American Journal of Respiratory and Critical Care Medicine (2019)
Abstract 11023: Development of a Biomimetic Tri-Leaflet Valved Tube Seeded with Wharton's Jelly-Derived Mesenchymal Stem Cells for Replacement of the Right Ventricular Outflow Tract
Authors: David Kalfa, Martin Bon, Valérie Vanneaux, Valérie Bellamy, Christian Choux, Claude Roques-Carmes, Jérôme Larghero, Patrick Bruneval, Philippe Menasché
Journal: Circulation (2012)

INTRODUCTION: Materials currently used for replacement of the Right Ventricular Outflow Tract (RVOT) in congenital heart diseases yield suboptimal results without growth potential, and may require ...
SAT0740-HPR Parity and the risk of developing rheumatoid arthritis: evidence from the malaysian epidemiological investigation of rheumatoid arthritis case-control study
Authors: C.L. Too, A.F. Nurul Aain, L.K. Tan, I.S. Lau, M.L. Nor Asiah, S. Salsabil, H. Heselynn, S. Nor Shuhaila, S. Wahinuddin, S.C. Gun, B. Eashwary, M.S. Mohd Shahrir, M. Ainon, R. Azmillah, O. Muhaini, B. Camilla, L. Padyukov, L. Alfredsson, L. Klareskog, M.L. Shahnaz
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Recent evidence from epidemiological studies has suggested that reproductive factors may play an important role for rheumatoid arthritis (RA) development. An inverse association was reported in several studies between parity and risk of RA. <h3>Objectives</h3> We investigated the association between parity and risk of anti-citrullinated peptide antibody (ACPA)-positive RA and ACPA-negative RA in the Malaysian population. <h3>Methods</h3> Data from the Malaysian Epidemiological Investigation of rheumatoid Arthritis (MyEIRA) population-based case control study involving 902 female early RA and 906 age and residential area-matched female controls were analysed. Parity history was assessed through a questionnaire. Parous women were compared with nulliparous women, by calculating odds ratio (OR) with 95% confidence intervals (Cl). <h3>Results</h3> Our findings demonstrated that parity was significantly associated with decreased risk of developing RA in the Malaysian population (RA versus controls, 82% vs. 89%, OR 0.58, 95% CI 0.44–0.77, p&lt;0.001). The association between parity and risk of RA was uniformly observed for ACPA-positive RA (OR 0.58, 95% CI 0.43–0.80, p&lt;0.001) and ACPA-negative RA (OR 0.58, 95% CI 0.40–0.84, p&lt;0.01) subsets, respectively. Compared with nulliparous women, the decreased risk was pronounced at the level of three and more live births for both ACPA-positive (OR 0.48, 95% CI 0.34–0.66, p&lt;0.001) and ACPA-negative RA (OR 0.46, 95% CI 0.31–0.68, p&lt;0.001) subsets. <h3>Conclusions</h3> Our data demonstrated that parity and level of three and more live births was associated with decreased risk of developing RA in the Malaysian population. The associated decrease risk was observed in both ACPA-positive and ACPA-negative RA subsets. <h3>References</h3> [1] Orellano C, Saevardottir S, Klareskog L, Karlson EW, Alfredsson L, Bengtsson C. Parity and the risk of developing rheumatoid arthritis: results from the Swedish Epidemiological Investigation of Rheumatoid Arthritis study. Ann Rheum Dis2014;73:752–755. [2] Ren L, Guo P, Sun Q, Liu H, Chen Y, Huang Y and Cai X. Number of parity and risk of rheumatoid arthritis in women: A dose-response meta-analysis of observational studies. J. Obstet. Gynaecol. Res2017;43(9):1428–1440. <h3>Disclosure of Interest</h3> None declared
Transcatheter Edge-to-Edge Repair for Tricuspid Regurgitation Is Associated With Right Ventricular Reverse Remodeling in Patients With Right-Sided Heart Failure
Authors: Mathias Orban, Daniel Braun, Simon Deseive, Lukas Stolz, Thomas J. Stocker, Konstantin Stark, Christopher Stremmel, Martin Orban, Christian Hagl, Steffen Massberg, Rebecca T. Hahn, Michael Nabauer, Jörg Hausleiter
Journal: JACC. Cardiovascular imaging (2019)
FRI0177 Assessing the value of whole body magnetic resonance imaging as to clinical examination to predict remission and relapse in early peripheral spondyloarthritis
Authors: T. Renson, P. Carron, S. Krabbe, L. Jans, A.-S. De Craemer, M. de Hooge, P. Jacques, M. Ostergaard, D. Elewaut, F. Van den Bosch
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Evaluation of disease activity and treatment response in peripheral spondyloarthritis (pSpA) is currently based upon clinical findings, laboratory tests and ultrasound examination. Whole-body magnetic resonance imaging (WB MRI) is a relatively new imaging technique that could offer additional information regarding the inflammatory status of joints, entheses and soft tissues. <h3>Objectives</h3> To determine A) the value of WB MRI, performed at baseline, in relation to clinical remission in pSpA and B) the value of subclinical inflammation, detected by WB MRI, at time of clinical remission in predicting flare after treatment withdrawal in pSpA. <h3>Methods</h3> Clinical REmission in peripheral SPondyloArthritis (CRESPA) is a placebo-controlled trial of golimumab treatment in 60 early (symptom duration &lt;12 weeks) pSpA patients (pts). All pts underwent a modified WB MRI at baseline and at the time of clinical remission when treatment was withdrawn. The WB MRI was performed by scanning multiple locations individually (using different coils) in order to investigate SpA-specific locations in detail. Several anatomical sites of pelvis and lower limbs were evaluated for bone marrow oedema (BME), synovitis and soft tissue inflammation (STI) by 3 readers, giving a score of 0 (no abnormalities), 1 (mild), 2 (moderate) or 3 (severe). For each site a mean of the scores of the 3 readers was calculated. For each patient at each time point, we calculated a sum score for synovitis, STI and BME separately adjacent to a total sum score. Changes scores are baseline minus remission sum scores. <h3>Results</h3> Pts reaching clinical remission had significant lower baseline BME sum scores then the non-remission group (mean 1.86 vs. 2.89, p=0.024). At the time of clinical remission 10/45 (22%) and 11/45 (24%) pts had residual talocrural and subtalar synovitis respectively. However, there was no statistically significant difference between patients who relapsed after treatment withdrawal and those who remained in remission concerning synovitis sum scores (p=0.497) as well as BME sum scores (p=0.741) and STI sum scores (p=0.131) at time of clinical remission (table 1). <h3>Conclusions</h3> Early pSpA pts who reach clinical remission have less BME on baseline WB MRI compared to those with ongoing disease activity. At time of clinical remission, a substantial part of the participants showed residual ankle synovitis on MRI. However, residual inflammatory lesions detected by WB MRI did not differ significantly between pts who relapsed after treatment withdrawal and those in ongoing clinical remission. <h3>Disclosure of Interest</h3> None declared
OP0053 Inflammatory disorders associated with trisomy 8 myelodysplastic syndromes : french retrospective case control study
Authors: N. Wesner, L. Drevon, A. Guedon, J.B. Fraison, S. Trad, J.E. Kahn, A. Aouba, J. Gillard, M. Ponsoye, T. Hanslik, C. Gourguechon, E. Liozon, K. Laribi, J. Rossignol, O. Hermine, L. Ades, F. Carrat, P. Fenaux, A. Mekinian, O. Fain
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Objectives</h3> We report myelodysplastic syndrome (MDS)-associated systemic inflammatory and autoimmune diseases (IADs) with cytogenetic trisomy 8, and describe their outcome, treatments efficacy and impact on MDS survival in a French multicenter retrospective study. <h3>Methods</h3> In this study, 21 patients with trisomy 8-MDS and IADs were analysed and compared to 103 MDS patients with trisomy 8 without IADs. <h3>Results</h3> The median age was 67 [59 – 80] years and the male/female ratio 0.9. The IADs were Behçet's or Behçet's-like disease in 11 (52%) cases, inflammatory arthritis in 4 (19%) cases, Sjögren's syndrome, autoimmune hemolytic anaemia, aseptic abscesses, polyarterits nodosa, Sweet's syndrome and unclassified vasculitis in one case each. Trisomy 8 karyotype was isolated in 8 cases (38%) and associated with other abnormalities in remaining cases. Seventeen (81%) IADs patients were treated (88% with steroids) with complete and partial response in 35% and 47%, respectively. A second-line therapy was required for steroid dependence or relapse in 38% of cases. The effect of MDS treatment on IADs could be assessed in 7 patients treated with Azacytidine : 5/13 (38%) achieved remission and 2/13 (15%) partial response of IADs. Compared with 103 trisomy 8-MDS/CMML patients without IADs, IADs patients were more often non-Caucasian (p=0.004), MDS subtype tended to be more frequently CRDM (p=0.09) and had more often a poor karyotype (p&lt;0.001). No survival difference was seen between patients with trisomy 8-MDS-associated IADs and without IADs. <h3>Conclusions</h3> The spectrum of IADs associated to trisomy 8-MDS is dominated by Behçet's disease, but may also be other various immune disorders. Steroid therapy is often effective, but sparing therapies are mostly necessary. <h3>Disclosure of Interest</h3> None declared
AB0266 Estimation of cerebrovascular reactivity in patients with rheumatoid arthritis
Authors: M. Salokhiddinov, U. Anarmetova, G. Haydarova
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Rheumatoid arthritis (RA) is a chronic autoimmune disease with high cardiovascular risk. Arterial hypertension (AH) is the most common comorbid condition in RA and one of the main risk factors for stroke. Chronic immune inflammation, characteristic of RA, also has a damaging effect on the vascular wall and can lead to a marked decrease in the compensatory possibilities of the cardiovascular system. It has been shown that the violation of cerebrovascular reactivity (CVR) significantly increases the risk of developing acute cerebral ischemia <h3>Objectives</h3> The goal is to study the condition of the CVR in RA patients, depending on the level of blood pressure (BP) <h3>Methods</h3> the study involved 70 patients with RA at the age of 59,2±7,3 years with the duration of RA 13±8,9 years were examined. The DAS28 index was 3.87±1.33. Depending on the level of blood pressure, two groups were isolated: group 1 (n=56) – patients with hypertension and group 2 (n=14) – with normal blood pressure. CVR was assessed by means of transcranial dopplerography of middle cerebral arteries (MCA) using hyperoxic (inhalation of 100% oxygen, phase of vasoconstriction) and hypercapnic (inhalation of 4% of a mixture of carbon dioxide with air, phase of vasodilation) of samples. <h3>Results</h3> The result showed that 15 (27%) patients of the I group and 3 (21%) – the II group had an adequate decrease in the linear velocities of the blood flow (LVBF) in the MCA. An insufficient reduction in hypervascular hypertension was found in 28<sup>50</sup>% and 8 (57%) patients, a paradoxical increase in the LVBF(perverse reaction) in 12 (21,4%) and 4 (28,5%) patients, respectively. In a hypercapnia trial, only about a third of patients registered an adequate increase in LBVF for hypercapnia. A decrease in the response occurred in 27 (48%) and 9 (61%) patients, excessive increase in LVBF (hyperergic reaction) – in 15 (26%) and 2 (14%) patients, respectively <h3>Conclusions</h3> There was a violation of the CVR on metabolic (hyperoxic and hypercapnic) stimuli based on the results of transcranial dopplerography of most RA patients, regardless of the level of blood pressure <h3>References</h3> [1] Machold KP, Stamm TA, Eberl GJM, et al. Very recent onset arthritis: Clinical, laboratory, and radiological findings during the first year of disease. Journal of Rheumatology2002;29(11):2278–2287. [2] Arndt U, Behrens F, Ziswiler HR, et al. Observational study of a patient and doctor directed pre-referral questionnaire for an early arthritis clinic. Rheumatology International2007;28(1):21–26. <h3>Disclosure of Interest</h3> None declared
Abstract 17502: Optimal Achieved Lipid Profiles for Asian Patients With Stable Coronary Artery Disease After Percutaneous Coronary Interventions
Authors: Chin-Chou Huang, Hsin-Bang Leu, Wei-Hsian Yin, Wei-Kung Tseng, Yen-Wen Wu, Tsung-Hsien Lin, Hung-I Yeh, Kuan-Cheng Chang, Ji-Hung Wang, Chau-Chung Wu, Jaw-Wen Chen
Journal: Circulation (2017)

Introduction: The concepts of lipid management for patients with stable coronary artery disease (CAD) are different according to UA and European guidelines. Whether these guidelines could be applie...
AB0053 A bioassay to measure tgfΒ activity reveals decreased tgfΒ activity in ssc serum
Authors: A. Van Caam, E. Vitters, F. van den Hoogen, M. Vonk, P. van der Kraan
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Systemic sclerosis (SSc) is a severe disease characterised by auto-immunity, vasculopathy and excessive fibrosis of connective tissues. The pathophysiology of SSc is still poorly understood, but its symptoms imply a role for dysregulated transforming growth factor β (TGFβ) signalling; <i>e.g.</i> this cytokine is known to regulate vascular and connective tissue biology. TGFβ circulates in blood in an inactive form bound to latency associated peptide and latent TGFβ binding proteins. This latent TGFβ first has to be activated before it can become bioactive. With the use of a bioassay, TGFβ's bioactivity can be measured in a complex mixture like serum, unlike with an ELISA which cannot take cellular activation processes into account. <h3>Objectives</h3> To determine the bioactivity of TGFβ in SSc serum compared to that of healthy control serum <h3>Methods</h3> Serum was collected of 10 SSc patients and 10 age and sex matched healthy controls. Primary human fibroblasts of 3 donors were transduced with CAGA<sub>12</sub>-luc which produces luciferase in response to TGFβ/Smad3 or BRE-luc which produces luciferase in response to BMP/Smad1/5. These cells were treated with 10% serum for 16 hour and luciferase activity was measured. To activate all TGFβ, sera were treated with 4M HCl for 1 hour at RT, after which pH was normalised with 4M NaOH. Controls were treated with HCl and NaOH simultaneously. To verify that TGFβ signalling was measured in this reporter assay, sera were treated with anti-TGFβ1/2/3 for 1 hour at RT before use. <h3>Results</h3> Control sera significantly induced reporter activity by 4.5-fold. However, SSc sera only induced a 2.5-fold increase in luciferase activity, indicating significantly lower bioactivity of TGFβ (p<i>&lt;</i>0.0001). This difference was not due to a difference in total TGFβ levels; after activation of all TGFβ both HC and SSc sera induced a similar 6-fold increase in signal strength. These data show that in HC sera approximately 75% of all TGFβ is bioactive compared to only 42% in SSc. Addition of anti-TGFβ1/2/3 inhibited all CAGA<sub>12</sub>-luc reporter activity (p<i>&lt;</i>0.0001) of both HC and SSc serum, and of both acidified and not acidified sera (p<i>&lt;</i>0.0001), showing that our bioassay is indeed TGFβ-dependent. To investigate if reduced bioactivity is a more general phenomenon we measured BMP activity. BMP proteins are structurally closely related to TGFβ and also circulate in inactive form. Both HC and SSc sera induced a similar 8-fold increase in BRE-luc activity, and this activity was increased to a 16-fold induction after acidification for both groups. BMPs in SSc sera are thus not less bioactive. This illustrates the uniqueness of our observation on TGFβ bioactivity. <h3>Conclusions</h3> TGFβ in SSc serum is less bioactive than in control serum whereas BMPs are not less bioactive. <h3>Disclosure of Interest</h3> None declared
Tibetan Enriched PKLR Variant Is Beneficial to High Altitude Adaption By Improving Oxygen Delivery
Authors: Jihyun Song, Virginia Abello, Ricardo Amaru, Adelina Sergueeva, Jainagul Isakova, Penelope A. Kosinski, Brigitte A. van Oirschot, Victor R. Gordeuk, Charles Kung, Richard van Wijk, Josef T. Prchal
Journal: Blood (2018)